1. Home
  2. GNLX vs CUE Comparison

GNLX vs CUE Comparison

Compare GNLX & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNLX
  • CUE
  • Stock Information
  • Founded
  • GNLX 2001
  • CUE 2014
  • Country
  • GNLX United States
  • CUE United States
  • Employees
  • GNLX N/A
  • CUE N/A
  • Industry
  • GNLX Biotechnology: Pharmaceutical Preparations
  • CUE Biotechnology: Pharmaceutical Preparations
  • Sector
  • GNLX Health Care
  • CUE Health Care
  • Exchange
  • GNLX Nasdaq
  • CUE Nasdaq
  • Market Cap
  • GNLX 85.0M
  • CUE 91.9M
  • IPO Year
  • GNLX 2023
  • CUE 2018
  • Fundamental
  • Price
  • GNLX $4.43
  • CUE $1.35
  • Analyst Decision
  • GNLX Strong Buy
  • CUE Strong Buy
  • Analyst Count
  • GNLX 4
  • CUE 5
  • Target Price
  • GNLX $18.25
  • CUE $5.00
  • AVG Volume (30 Days)
  • GNLX 290.3K
  • CUE 277.1K
  • Earning Date
  • GNLX 03-31-2025
  • CUE 03-10-2025
  • Dividend Yield
  • GNLX N/A
  • CUE N/A
  • EPS Growth
  • GNLX N/A
  • CUE N/A
  • EPS
  • GNLX N/A
  • CUE N/A
  • Revenue
  • GNLX $8,000.00
  • CUE $9,532,000.00
  • Revenue This Year
  • GNLX N/A
  • CUE $73.11
  • Revenue Next Year
  • GNLX N/A
  • CUE $11.02
  • P/E Ratio
  • GNLX N/A
  • CUE N/A
  • Revenue Growth
  • GNLX N/A
  • CUE 149.53
  • 52 Week Low
  • GNLX $1.60
  • CUE $0.45
  • 52 Week High
  • GNLX $9.82
  • CUE $2.58
  • Technical
  • Relative Strength Index (RSI)
  • GNLX 72.82
  • CUE 51.23
  • Support Level
  • GNLX $3.20
  • CUE $1.27
  • Resistance Level
  • GNLX $4.23
  • CUE $1.50
  • Average True Range (ATR)
  • GNLX 0.53
  • CUE 0.13
  • MACD
  • GNLX 0.09
  • CUE -0.00
  • Stochastic Oscillator
  • GNLX 86.86
  • CUE 61.44

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Share on Social Networks: